13
2025-06
SUZHOU, China, May 28, 2025 /PRNewswire/ -- In the newly announced entry list of the Inspiration Hive zone at the 2025 New York Society of Cosmetic Chemists (NYSCC) exhibition, Kintor's innovative ingredient KT-939 has been selected as the only "Chinese Ingredient" among the numerous global ones. It will compete with global industry giants such as Ashland, DSM-Firmenich, and Eastman, marking a groundbreaking milestone that China's cosmetic ingredient R&D stands at the forefront of global innovation.
14
2020-09
Kintor Pharma to Apply to Launch its Prostate Cancer Drug Next Season
In an interview with the Hong Kong Economic Journal, Kintor Pharmaceutical's (09939) Chief Financial Officer Lu Yan noted that the company will submit its new drug application (NDA) for its core product GT0918 for the treatment of prostate cancer next season.
02
2020-09
China’s New Drugs on Way to Treating Male Baldness
According to the Insight database, KX-826, a drug of Chinese drugmaker Kintor Pharmaceutical currently in phase II clinical phase, has also been developed for the treatment of AGA.
19
2020-05
On the last day of 2019, Kintor’s application for a HKEX listing had attracted industry attention. It was reported that with this Hong Kong stock IPO listing on May 22nd 2020 and the global sale of 92
09
2020-05
In 2008, as the first group of pioneers to return to China to conduct research on small molecule anticancer drugs, Dr. Youzhi Tong said, there were not many companies doing new drug research and devel
07
2020-05
Ten years of consistent effort finally bear fruit
In 2008, after nearly 20 years studying and working in the US, Dr. Youzhi Tong made a momentous decision to return to China and start a new drug discovery company. “People who choose to start a busine
Find Us
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Complaints and Suggestions Tel: +86 512 62639935 Email: pr@kintor.com.cn
Copyright: Kintor Pharmaceutical Limited retains all copyrights.
Powered by 300.cn